brain tumours, Celgene, digital health, glioblastoma, medical devices, Novocure, Oncology, Optune
0 Comment
Novocure’s Optune will be tested alongside investigational Celgene drug marizomib.
brain cancer, glioblastoma, medical devices, Novocure, Optune
0 Comment
Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
glioblastoma, medical devices, Novocure, Optune, ovarian cancer, TTFs
0 Comment
Novocure’s Optune device shown to be safe and tolerable in recurrent ovarian cancer.
